ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
Friday, 28 March 2025 () AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter (“Q3”) of its 2025 fiscal year (“FY25”), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug discovery sector, our recent milestones underscore the growing recognition of our innovative AI and growth potential. Notably, we've secured a strategic part
Friday, 28 March 2025 ()
